Vitiligo – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Vitiligo – Pipeline Review, H1 2017’, provides an overview of the Vitiligo pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vitiligo, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vitiligo and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Vitiligo

The report reviews pipeline therapeutics for Vitiligo by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Vitiligo therapeutics and enlists all their major and minor projects

The report assesses Vitiligo therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Vitiligo

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Vitiligo

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Vitiligo pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aclaris Therapeutics Inc

Biocon Ltd

Bristol-Myers Squibb Company

Celgene Corp

Clinuvel Pharmaceuticals Ltd

Incyte Corp

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Vitiligo - Overview

Vitiligo - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Vitiligo - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Vitiligo - Companies Involved in Therapeutics Development

Aclaris Therapeutics Inc

Biocon Ltd

Bristol-Myers Squibb Company

Celgene Corp

Clinuvel Pharmaceuticals Ltd

Incyte Corp

Vitiligo - Drug Profiles

abatacept - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

afamelanotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

apremilast - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-50001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATI-50002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

itolizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ruxolitinib phosphate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VLRX-001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vitiligo - Dormant Projects

Vitiligo - Product Development Milestones

Featured News & Press Releases

Dec 03, 2015: Positive preliminary results in Singaporean vitiligo study

Dec 03, 2015: Update on North American vitiligo program for SCENESSE

May 05, 2015: Clinuvel announces innovative melanocortin for new indications

Mar 20, 2015: SCENESSE vitiligo data presented at world’s largest dermatology conference

Sep 19, 2014: SCENESSE vitiligo study results published in JAMA Dermatology

May 06, 2014: Clinuvel’s Phase II vitiligo study commences in Singapore

Mar 20, 2014: SCENESSE data to feature at American Academy of Dermatology

Nov 04, 2013: Clinuvel to start a Phase II vitiligo study in Singapore

Sep 02, 2013: Five month study follow up shows SCENESSE combination treatment provided stable repigmentation in vitiligo patients

Mar 01, 2013: SCENESSE data to be presented at American Academy of Dermatology, San Gallicano Rare Disease conference

Dec 19, 2012: Clinuvel Pharma Announces Results From Phase IIa Pilot Study Of Scenesse In Vitiligo

Oct 16, 2012: Observations from Clinuvels US vitiligo study published

Mar 15, 2012: Observations from Clinuvels vitiligo and EPP programs being presented at the

Mar 02, 2011: Clinuvel Announces FDA Approval For Vitiligo Drug Trial

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Vitiligo, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Vitiligo – Pipeline by Aclaris Therapeutics Inc, H1 2017

Vitiligo – Pipeline by Biocon Ltd, H1 2017

Vitiligo – Pipeline by Bristol-Myers Squibb Company, H1 2017

Vitiligo – Pipeline by Celgene Corp, H1 2017

Vitiligo – Pipeline by Clinuvel Pharmaceuticals Ltd, H1 2017

Vitiligo – Pipeline by Incyte Corp, H1 2017

Vitiligo – Dormant Projects, H1 2017

List of Figures

List of Figures

Number of Products under Development for Vitiligo, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Targets, H1 2017

Number of Products by Stage and Targets, H1 2017

Number of Products by Mechanism of Actions, H1 2017

Number of Products by Stage and Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports